AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03674294
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the current clinical trial, placebo oral tablet is provided as a substance for Aprepitant with no active therapeutic effect.
Trial: NCT04347954
Drug: Isotonic saline 0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two sprays to each nare of isotonic saline (0.9% NaCl) via nasal spray bottle, four times a day
Trial: NCT01113333
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:injection~Route of administration: intra-articular
Trial: NCT01113333
Drug: SAR113945
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:injection~Route of administration: intra-articular
Trial: NCT00197886
Drug: Changing dose of norepinephrine and blood pressure
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00310089
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01149525
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral solution, twice per day (morning/evening), during 3 months
Trial: NCT00367991
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline to match active drug (rHuEpo)
Trial: NCT01733238
Drug: PNT2258
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00748306
Drug: GSK2190915 - 100mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor
Trial: NCT00748306
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Intervention Drug
Trial: NCT00310089
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00790790
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY545694 placebo BID po for 5 weeks
Trial: NCT00790790
Drug: LY545694 49 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY545694 49 mg BID po for 5 weeks.
Trial: NCT00790790
Drug: LY545694 105 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY545694 105 mg BID po for 5 weeks.
Trial: NCT03897348
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral medication
Trial: NCT02880241
Drug: MMV390048
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets of 20mg each
Trial: NCT00165451
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration twice daily starting at 100mg/dose for 6 months.
Trial: NCT00165451
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral administration once daily at night starting at 3.5mg/m2 3 weeks on and 3 weeks off for 6 months.
Trial: NCT03920215
Drug: OC-01 Low Dose, 0.12 mg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OC-01 (varenicline) nasal spray
Trial: NCT03920215
Drug: OC-01 Mid Dose, 0.6 mg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OC-01 (varenicline) nasal spray
Trial: NCT03920215
Drug: OC-01 High Dose, 1.2 mg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OC-01 (varenicline) nasal spray
Trial: NCT03920215
Drug: Placebo (vehicle) nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (vehicle) nasal spray
Trial: NCT01802866
Drug: ACU-4429
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take orally once daily for 24 months
Trial: NCT01802866
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take orally once daily for 24 months
Trial: NCT02625467
Drug: Treatment posterior to surgery
RxNorm normalized name: posterior pituitary hormones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoroquinolone topical antibiotic (Moxifloxacin, Vigamox) and topical steroid (Prednisolone Acetate Ophthalmic Suspension, Pred Forte)
Trial: NCT01160224
Drug: GW766944
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: GW766944 (Active Drug Treatment)
Trial: NCT00407641
Drug: Heparin administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive Heparin as an anticoagulant during the HD session.
Trial: NCT01600105
Drug: Perfusion MRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1) Assess the role of a new FDA approved blood pool gadolinium contrast agent (gadofosveset trisodium, Ablavar, Lantheus) for the measurement of liver MR Perfusion, compared to extra-cellular contrast agents.
Trial: NCT03052361
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: similar looking and tasting liquid placebo
Trial: NCT02104765
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously.
Trial: NCT01970618
Drug: RV1162 single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safety and tolerability of single escalating doses
Trial: NCT01970618
Drug: RV1162 matching placebo single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safety and tolerability of single escalating doses
Trial: NCT01970618
Drug: RV1162: 7 day repeat dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safety and tolerability of a repeat dose
Trial: NCT01970618
Drug: RV1162 matching placebo: 7 day repeat dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safety and tolerability of a repeat dose
Trial: NCT01970618
Drug: RV1162: 14 day repeat dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safety and tolerability of repeat escalating doses
Trial: NCT01970618
Drug: RV1162 matching placebo: 14 day repeat dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safety and tolerability of repeat escalating doses
Trial: NCT00305591
Drug: l-ornithine l-aspartate
RxNorm normalized name: L-ornithine L-aspartate
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02613806
Drug: Dexmeditomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmeditomidine 0.2 ug/kg·h will be administered to participants by intravenous infusion at the beginning of the surgery,and continued till end of surgery.
Trial: NCT02613806
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isovolumetric normal saline will be administered to participants by intravenous infusion at the beginning of the surgery,and continued till end of surgery.
Trial: NCT00028964
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03008018
Drug: KA2507
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KA2507, an orally-active new chemical entity, is a potent and selective inhibitor of the HDAC6 enzyme, with potential clinical utility in the treatment of melanoma and other solid tumors. KA2507 has been shown to display potent in vitro activity in a range of cancer cell lines, including melanoma cell lines. KA2507 exerts potent in vivo efficacy in a syngeneic model of B16 melanoma. Here, the combination of the agent's direct tumor growth inhibition and metastasis suppression, coupled with its immunotherapeutic activity - demonstrated by decreased expression of STAT-3 and PD-L1 and increased expression of acetylated tubulin, gp100 and MHC Class I in tumors - have been observed.
Trial: NCT00028964
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02876484
Drug: Chenodeoxycholic Acid
RxNorm normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00509535
Drug: vitreoscilla filiformis cream
RxNorm normalized name: Vitreoscilla lysate extract
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02805894
Drug: NBTXR3 activated by IMRT only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single local administration of NBTXR3 by injection into the prostate gland prior to the IMRT treatment
Trial: NCT02805894
Drug: NBTXR3 activated by Brachytherapy & IMRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single local administration of NBTXR3 by injection into the prostate gland prior to the Brachytherapy \& IMRT treatment
Trial: NCT05076656
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in a white, gelatin capsule (orally), with powder milk
Trial: NCT01385657
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A total of 4 doses were administered.
Trial: NCT01582399
Drug: ASKP1240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous(IV) infusion and subcutaneous (SC)
Trial: NCT00688519
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face and scalp).
Trial: NCT02101190
Drug: BIA 9-1067
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opicapone, OPC
Trial: NCT00009646
Drug: indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indocid P.D.A., Merck Frosst, Kirkland, Que., Canada, and Merck, West Point, Pa
Trial: NCT00009646
Drug: Indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.1 mg per kilogram of body weight
Trial: NCT00009646
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg per kilogram of body weight
Trial: NCT00003549
Drug: CMF regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00003549
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003549
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003549
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01698723
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04007367
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAGE-217 matching placebo capsule
Trial: NCT02171442
Drug: BIBR 953 ZW Intravenously
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg, 2.8 MBq (76 µCi)
Trial: NCT01756196
Drug: Spinal Steroid Injection
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid Injection
Trial: NCT03621657
Drug: Low Dose FMT Capsule DE
RxNorm normalized name: sangre de grado
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 FMT Capsule DE along with antibiotic; followed by five capsules FMT Capsule DE x 7 days post-antibiotic course.
Trial: NCT03621657
Drug: Single Dose FMT Capsule DE
RxNorm normalized name: sangre de grado
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 pill FMT Capsule DE treatment x 1, 48-72 hours following completion of antibiotic treatment.
Trial: NCT03621657
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five capsules per day along with antibiotic; followed by five capsules per day for seven days post-antibiotic treatment.
Trial: NCT00862524
Drug: ARRY-334543, EGFR/ErbB2 inhibitor; oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple dose, escalating
Trial: NCT01815450
Drug: BLI1100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BLI1100 topical cream
Trial: NCT01815450
Drug: BLI1100 - modified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BLI1100 topical cream
Trial: NCT01815450
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo topical cream
Trial: NCT02551055
Drug: MLN1117
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MLN1117 Tablets
Trial: NCT01522326
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 400mg tablet. Take one dose by mouth.
Trial: NCT00430300
Drug: UK-432,097
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulated as a dry powder, supplied as capsules and administered using an atomizer device. Given as either 150mcg, 450mcg or 1350mcg BID.
Trial: NCT00430300
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules containing 100% lactose administered BID using an atomizer device
Trial: NCT01899768
Drug: GSK2339345
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clear colorless solution in clear glass vial for oral inhalation via aqueous droplet inhaler with unit dose strength of 1000 microgram (mcg) inhaled in two actuations.
Trial: NCT01899768
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clear colorless solution of 0.9% sodium chloride for oral inhalation via aqueous droplet inhaler inhaled in two actuations.
Trial: NCT02204059
Drug: hMAb BIWA 4
RxNorm normalized name: BREATHING CIRCUIT,BIWAZE COUGH,W/MOUTHPIECE,STANDARD
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01941563
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01042925
Drug: XL147 (SAR245408)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered orally once daily as tablet(s)
Trial: NCT01633788
Drug: AGN-195263 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop of AGN-195263 0.1% instilled in each eye twice daily.
Trial: NCT01633788
Drug: AGN-195263 0.03%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop of AGN-195263 0.03% instilled in each eye twice daily.
Trial: NCT01633788
Drug: AGN-195263 0.01%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop of AGN-195263 0.01% instilled in each eye twice daily.
Trial: NCT00092664
Drug: MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 14 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01633788
Drug: AGN-195263 Vehicle
RxNorm normalized name: VITEX AGNUS-CASTUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop of AGN-195263 vehicle (placebo) instilled in each eye twice daily.
Trial: NCT01849055
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01849055
Drug: LY3023703
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01849055
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT03930927
Drug: remineralizing agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: enamel regeneration
Trial: NCT03531710
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection
Trial: NCT04012541
Drug: post-myocardial infarction management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aspirin, clopidogrel, ticagrelor
Trial: NCT00865202
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Similar appearing placebo administered post-operatively (1 enterally TID) for a total of nine doses or discharge from ICU (whichever occurs first)
Trial: NCT01459445
Drug: Metformin, Ethinylestradiol 30µg-Drospirenone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin: 1700 mg /day (twice per day)-6 months; EE30µg-drospirenone: 1 tb/day, 21 days/month, 6 months
Trial: NCT01694823
Drug: CS-ACI
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procedure: Self-control. Cells Sheet-Autologous Chondrocyte Implantation(CS-ACI) includes an arthroscopy for harvesting of cartilage 6-8 weeks prior to the open cartilage surgery. Other Names:~Cells Sheet-Autologous Chondrocyte Implantation （CS-ACI）
Trial: NCT00623766
Drug: Corticosteroid: Methylprednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with methylprednisolone
Trial: NCT02082665
Drug: Rosuvastatin10 mg tablet
RxNorm normalized name: rosuvastatin 10 MG
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Commercially available Rosuvastatin 10 mg tablets will be supplied. Single oral dose of Rosuvastatin 10 mg will be administered on Day 1, 8 and 22
Trial: NCT02707224
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Investigational product is prescribed to all of randomized subjects
Trial: NCT03813199
Drug: ABX464 50mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABX464 is a new anti-inflammatory drug
Trial: NCT03813199
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo matching with ABX464
Trial: NCT03813199
Drug: ABX464 100mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABX464 is a new anti-inflammatory drug
Trial: NCT03813199
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MTX ≥ 10 mg/week will be given at previous dose regimen kept stable throughout the study
Trial: NCT01511640
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo 2x daily for duration of study
Trial: NCT03297944
Drug: Placebo (PLC/PLC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered at night, placebo administered in the morning.
Trial: NCT01703923
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02695381
Drug: Etodolac-lidocaine topical patch
RxNorm normalized name: lidocaine Medicated Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily
Trial: NCT02695381
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily
Trial: NCT03547791
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of normal saline 3ml twice 24hours apart
Trial: NCT04510649
Drug: Part B
RxNorm normalized name: Hem-Care Premium 7-Part Blend Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: in Part B, all subjects will receive Surufatinib 300 mg in a single dose on study days 1 and 12 and receive Rifampin 600 mg single dose on study days 5 through 16
Trial: NCT00394407
Drug: sliding scale regular insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSRI acqhs
Trial: NCT00394407
Drug: glargine basal insulin and glulisine prandial insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: glargine insulin once a day and glulisine insulin three times a day as long as patient eating
Trial: NCT02999906
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (sugar pill) for three times daily oral administration
Trial: NCT00623766
Drug: Corticosteroid: Prednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with prednisolone
Trial: NCT00020917
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00020917
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03278444
Drug: Arginine hydrochloride
RxNorm normalized name: Arginine Hydrochloride
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arginine hydrochloride injection 5g/dose; 40g/d; ivgtt; sustained medication for 24 days; drug withdrawal for 4 days.
Trial: NCT01084473
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9 % NaCl will be infused.
Trial: NCT00515944
Drug: Botulinum neurotoxin type A, free of complexing proteins
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04476108
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT00312728
Drug: First-Line Chemotherapy Agents
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carboplatin, cisplatin, paclitaxel, docetaxel, gemcitabine, vinorelbine, pemetrexed, or erlotinib administered on Day 1 of every 21-day cycle except gemcitabine, which was administered on Days 1 and 8 of every cycle. Agents were administered as a platinum doublet, or erlotinib alone, at the investigator's discretion. Chemotherapy was administered for a total of 6 planned cycles (up to 8 cycles with prior approval from the Medical Monitor), followed by single-agent bevacizumab therapy. The chemotherapy regimen was to be consistent throughout the study. Erlotinib was administered orally daily.~All agents were dosed and administered per institutional standards using the respective package insert as a guideline.
Trial: NCT00312728
Drug: Second-Line Chemotherapy Agents
RxNorm normalized name: Gallus gallus gizzard lining preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib, pemetrexed, docetaxel, or chemotherapy at the investigator's discretion. Erlotinib was administered orally daily; pemetrexed and docetaxel were administered IV on Day 1 of every 21-day cycle. Single-agent bevacizumab therapy could be continued at the investigator's discretion if the second-line agent was discontinued.~All agents were dosed and administered per institutional standards using the respective package insert as a guideline.